I want to begin with a simple observation. The questions I explain in clinic today are not the same ones I was asked five years ago.

This article is a reflection of that change. Here we go.

For a long time, endometrial cancer was seen as a relatively straightforward disease. Stage, grade, depth of myometrial invasion, and LVSI largely dictated adjuvant treatment decisions. Radiation helped with local control. Chemotherapy helped with distant control. Overall survival rarely moved.

That framework served us well, but it also left us uncomfortable.

We all remember patients who recurred despite “low-risk” features, and others who did remarkably well despite aggressive histology. Biology was clearly playing a bigger role than our traditional labels allowed.

Molecular oncology has changed that conversation.

From histology to biology

Endometrial cancer is no longer a single disease with varying grades of severity. It is a group of biologically distinct entities that behave very differently, even when stage and grade look identical.

The now-familiar molecular subgroups have helped explain what we were already sensing clinically:

• Tumours with POLE mutations behave indolently, often regardless of grade.
• Mismatch repair deficient tumors sit in the middle, with variable outcomes and therapeutic implications beyond radiation.
• p53 abnormal tumors consistently show aggressive behavior and higher recurrence risk.
• The NSMP group remains heterogeneous and still demands careful clinicopathological judgment.

 

This classification does not replace histology. It refines it.

Why this matters in daily practice

Radiation therapy in endometrial cancer has always been about balance. It improves loco-regional control, but it does not improve overall survival. That reality forces us to ask an uncomfortable question every time we recommend adjuvant treatment.

Are we helping this patient, or are we simply treating risk factors? Molecular profiling helps answer that question with greater precision.

It allows us to identify patients who are unlikely to benefit from adjuvant radiation and those who may actually need escalation rather than de-escalation. Importantly, it shifts the goal from treating groups to treating biology.

Lessons from recent data

Recent prospective data have shown that a substantial proportion of women with early stage, high-intermediate risk disease can safely avoid adjuvant radiation when their molecular profile is favorable, without compromising meaningful oncologic outcomes.

Equally important is the opposite finding.

Patients with unfavorable molecular features appear to benefit from treatment intensification, particularly in terms of locoregional control. This reinforces something radiation oncologists have long suspected. Some tumors are aggressive from the start, even when they look deceptively early.

What is striking is not just the safety of de-escalation, but the confidence with which it can now be offered.

What this means for multidisciplinary care

For surgeons, this means surgical staging alone is no longer the final word on prognosis.

For radiation oncologists, it sharpens our role. We are no longer simply deciding between vaginal brachytherapy and pelvic radiation based on risk categories. We are tailoring treatment to tumour behaviour.

For patients, it means fewer unnecessary treatments, less toxicity, and more informed discussions about why treatment is or is not recommended.

Where we still need caution

Molecular classification is not a magic switch.

Access, cost, turnaround time, and interpretation still vary across centers. The NSMP group remains biologically diverse, and clinical judgment continues to matter. Molecular data should inform decisions, not override common sense.

Most importantly, these tools must be integrated thoughtfully into real-world workflows, especially in settings where resources are limited.

A quiet but important shift

Endometrial cancer management has not changed overnight. There has been no dramatic survival curve shift. What has changed is subtler and arguably more important.

We are becoming better at choosing who truly needs treatment and who does not.

In that sense, molecular oncology has not complicated endometrial cancer care.

It has made it more honest.

As William Osler reminded us, a good physician treats the disease. A great physician treats the patient who has the disease. Molecular classification helps us do that with greater clarity.

Sometimes, better treatment begins with better understanding.